BioMoti is runner-up at this year’s prestigious Genesis Awards in the BioPharma innovation category along with Domainex and Thiologics. The category winner, announced at a special awards dinner following the conclusion of the Genesis 2011 conference on the first of December, was Immunocore. On the night, there was also a win for Scottish Health Innovations (SHIL) in the MedTech innovation category.
Harriet Fear, CEO of One Nucleus said that competition was fierce and showed that despite the current economic downturn, there is a wealth of innovation in the UK life sciences sector: “Companies such as Immunocore and SHIL show that innovation is alive and kicking in the UK. One Nucleus wanted to find a way to provide continued practical encouragement and have thus restructured the Genesis Awards. We decided the best way was to reduce the awards to two – BioPharma Innovation and Medtech Innovation – and give them real value. Thus the winners each receive £25,000 worth of pledged benefits from leading One Nucleus members in key areas along the company development chain – a wide range of pivotal support ranging from patenting to regulatory filing and access to potential partners and investors.”